Tumeur myofibroblastique inflammatoire récurrente avec triple localisation, rénale, rétropéritonéale et ganglionnaire

Fibronectin as an adjuvant in the diagnosis of oral inflammatory myofibroblastic tumor

“…Extrapulmonary IMTs seem to exhibit a more favorable clinical course and treatment outcome, evolving with lower rates of recurrence, malignant transformation, metastasis, and mortality (5). One noteworthy feature is that oral IMT seems to behave differently from IMT occurring elsewhere in body (11), displaying variable local recurrence and not reported metastasis (6). There may be a need to recognize it as a separate entity.…”

“…Some authors widely consider it a benign neoplastic lesion (6), and others support a reactive etiology (10), since the rapid growth and subsequent indolent behavior of most oral IMT are similar to that of many common reactive oral lesions (5). Differently, in other sites, this condition can behave in a more aggressive or even malignant way (11), constituting a true neoplastic process due to the potential for local recurrence, development of multifocal tumors, infiltrative local growth, and even distant metastasis (12). Histologically, various aspects can be seen.…”

“…So, the knowledge of the different histologic patterns of IMT, identification of a predominant inflammatory component and immunohistochemical study allow distinction between these entities, being helpful to the accurate diagnosis (5), as emphasized by the present report, and also preventing a more aggressive surgical procedure. Management of IMT should entail complete surgical resection (5,6), and since IMT may present a low-grade malignancy, longer follow-up is needed (11). Extrapulmonary IMTs seem to exhibit a more favorable clinical course and treatment outcome, evolving with lower rates of recurrence, malignant transformation, metastasis, and mortality (5).…”